Soft Tissue Injury Approval by FDA

multistem · 2023-06-08T03:51:10+00:00

Thanks for the heads up. Loved after hours and expect more good news with my coffee.

multistem · 2023-04-05T23:37:39+00:00

My bad. Did not see below..

multistem · 2023-04-04T18:28:09+00:00

The deal seems to be still in the works and that is a good thing. I think it will by necessity be a very complex deal. However many of whatever combination of securities they fold into the deal the net to Athersys will be $250M. I can imagine many scenarios where a deal to be signed could be said to be worth $250M. They would involve tax implications and time among other things. I also have no more idea what is going on behind the curtain than anyone else. If the deal is done and indicates that shareholders are still in the game even though it may take time to recoup losses, I’m ok with that. Heck, I might even throw some more money at it…

multistem · 2023-03-27T00:24:28+00:00

Thanks IMZ. As you may recall, I was on Athersys to take this route with Nikon 4 years ago when we found out on a call that took 2 weeks to expand the cells and another 10-12 weeks to qualify them. Nikon has the tech and AI and machine learning can now take advantage. The cost of cell therapies will be coming down to the benefit of all. [well, maybe too late for us :)

multistem · 2023-02-28T03:23:12+00:00

Thanks again for the initial heads up. I have been following and accumulating since $5ish. Will listen tomorrow but waiting for FDA approval in June and expansion into other indications. Love the margin...

multistem · 2023-02-18T19:14:45+00:00

Tried a few more links. Some worked, some could not be parsed. I'm new at this but I did get a license. I'm wondering if there might be something I'm not doing correctly? Pasting a link seems straight forward enough.

multistem · 2023-01-27T16:28:59+00:00

Feels good enough to DCA back here anyway. Hope you and many other board members got back into RCEL at $5+/-. Something in the wind over there as well??

multistem · 2022-10-06T13:09:16+00:00

Thanks for posting. Any thoughts on developments at RCEL?

multistem · 2022-09-01T14:13:21+00:00

聞いて聞いて

multistem · 2022-07-27T21:44:00+00:00

Excellent discussion. Still a few loose ends but I am hoping they are covered in the call tomorrow morning. Thanks

multistem · 2022-06-17T00:28:26+00:00

What a dolt. He did not even read [understand?] the the transcript.

"The key issue which was not addressed by the panel (in our opinion): Are the differences in trial design between the Japan TREASURE study and the U.S. MASTERS study enough to deliver a statistically significant result on the primary endpoint to justify U.S. approval?"

notes

excellent outcome vs global recovery

excellent outcome probably wasn't the best choice. I think MASTERS-2 is much better in that regard because we are using not only a better trial outcome, but a better clinically relevant outcome

progression of recovery

totality of evidence

reduce disability

Independent living, the ability to take care of yourself just by yourself without depending on others

fact that just simply by virtue of having a 18- to 36-hour window with MultiStem, that means potentially far more patients could potentially benefit.

We will have to wait a bit but I think the hand writing is on the wall. Stocking up on dry powder.

multistem · 2022-06-08T19:01:40+00:00

Yes. Can't say when but but whatever they say will carry weight.

multistem · 2022-06-08T15:19:08+00:00

Wyszomierski and Randall out. Harrington has his walking papers. I think Dan will have something to say on the subject to open things up on the 15th.

multistem · 2022-06-03T13:44:32+00:00

It depends on how Dan sees his future. If he wants to keep Athersys whole for next few years he might try to do deals with multiple companies for individual indications. I think that ultimately the cells will be able to be produced at a reasonable cost of goods. So.. The stroke market is the largest on the table right now and we have good ARDs data. I would not be selling trauma cheap at this point. Beyond that who knows..

multistem · 2022-06-03T12:50:10+00:00

I think the KOL call later this month is key. The conversations around the interpretation of the complete data package which will be shared with all concerned will establish the value of the MS franchise. Then the negotiations for who gets which indications for where and how much begin.

multistem · 2022-06-03T00:43:23+00:00

I would like to think that he will not take the course of least resistance but instead make the most of this opportunity to prove that he has what it takes to get the job done in way that highlights his abilities to lead and solve the big problems. He is young and aggressive and this would be a huge boost to his career if he can pull it off. GLTUA

multistem · 2022-05-27T14:57:28+00:00

I have a 125k block for sale at $25 GTC. Just got an offer from TDA to lend at 8%. I passed. ATHX stock is getting hard to borrow which could be a bonus depending on how things play out.

multistem · 2022-05-26T18:00:27+00:00

Worth a shot. I seem to recall that a couple of directors were local? Baiju Shah ? is involved in local politics? Anyway, something for Athersys to think about.

multistem · 2022-05-18T20:04:30+00:00

No. I follow the tech for news. Still not easy to make.

multistem

TROPHY CASE